{"links":{"html":"https://www.erudio.com/reports/neo-blast-nct06537154","json":"https://www.erudio.com/reports/neo-blast-nct06537154.json","markdown":"https://www.erudio.com/reports/neo-blast-nct06537154.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"neo-blast-06537154"}},"request":"https://www.erudio.com/contact?report=neo-blast-06537154"},"offer":{"cited_commentary_sources":21,"verified_hcp_statements":211,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":15,"optional":true,"price_per_verified_person_usd":15,"price_usd":225,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"neo-blast-nct06537154"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=neo-blast-06537154","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/neo-blast-nct06537154","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T12:22:11.869649Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2)"},{"claim_count":7,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":4,"title":"Primary endpoint: Metastasis free survival at 2 years (phase 3)"},{"claim_count":10,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":19,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":29,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":9,"title":"The comparison"},{"claim_count":20,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":7,"title":"Safety and tolerability"},{"claim_count":19,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":46,"coverage":"discussed","id":"A1","source_count":8,"title":"Clinical complete response, biomarker interpretation and local versus systemic risk"},{"claim_count":29,"coverage":"discussed","id":"A2","source_count":13,"title":"Antecedent evidence and the threshold for changing practice"},{"claim_count":42,"coverage":"discussed","id":"A3","source_count":4,"title":"Upfront systemic choice, access, sequencing and referral"},{"claim_count":39,"coverage":"discussed","id":"A4","source_count":4,"title":"Systemic exposure, adjuvant necessity and alternative research strategies"},{"claim_count":20,"coverage":"discussed","id":"A5","source_count":7,"title":"Patient-valued non-inferiority, surveillance burden and decision support"}],"counts":{"cited_sources":23,"claims_by_expression_type":{"comparison":6,"experience":12,"interpretation":45,"opinion":68,"primary_context":3,"question":35,"restatement":17,"uncertainty":8,"unspecified":17},"claims_by_kind":{"interpretation":2,"protocol_statement":1,"publication_statement":4,"source_observation":204},"clinician_statements":63,"evidence_units":142,"findings":11,"people_cited":19,"people_identity_verified":15,"people_total":19,"screened_sources":31,"verified_claims":211},"findings_index":[{"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":1,"views":7},"has_counterview":true,"limitations":2,"links":{"context":1,"support":18},"ma_question":true,"named_voices":6,"passages":17,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"High response rates are not treated as permission to omit definitive local therapy"},{"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":2,"views":4},"has_counterview":true,"limitations":1,"links":{"context":1,"support":11},"ma_question":true,"named_voices":5,"passages":6,"sources":5,"sources_by_kind":{"commentary":3,"media":2}},"title":"The proposed cCR assessment is composite; no single negative test establishes eligibility"},{"id":"F3","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":0,"views":12},"has_counterview":true,"limitations":2,"links":{"context":1,"support":15},"ma_question":true,"named_voices":1,"passages":7,"sources":2,"sources_by_kind":{"media":2}},"title":"ctDNA informs systemic-risk selection but does not resolve local disease or surveillance"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":1,"questions":4,"restated":0,"views":4},"has_counterview":true,"limitations":2,"links":{"context":2,"support":14},"ma_question":true,"named_voices":4,"passages":13,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Radiotherapy is a connected alternative, but its incremental role after systemic response is disputed"},{"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":6,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"How should RETAIN and other precursor studies inform local-treatment omission?"},{"id":"F6","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":7},"has_counterview":true,"limitations":2,"links":{"context":1,"support":13},"ma_question":true,"named_voices":1,"passages":6,"sources":4,"sources_by_kind":{"media":3,"publication":1}},"title":"Randomization feasibility, comparator flexibility and physician participation are substantive concerns"},{"id":"F7","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":2,"passages":6,"sources":5,"sources_by_kind":{"media":5}},"title":"What would non-inferiority permit, and which trade-offs would patients accept?"},{"id":"F8","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":5,"restated":1,"views":5},"has_counterview":true,"limitations":4,"links":{"context":3,"support":16},"ma_question":true,"named_voices":1,"passages":15,"sources":1,"sources_by_kind":{"media":1}},"title":"Systemic-first reasoning challenges surgery-first practice, with urgent-surgery exceptions"},{"id":"F9","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":3,"views":6},"has_counterview":true,"limitations":3,"links":{"context":3,"support":15},"ma_question":true,"named_voices":3,"passages":16,"sources":2,"sources_by_kind":{"media":2}},"title":"Regimen preference is qualified by access, platinum alternatives and evidence maturity"},{"id":"F10","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":3,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":4,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Treatment duration and adjuvant toxicity remain unresolved costs of local de-escalation"},{"id":"F11","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":0,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":2,"passages":11,"sources":1,"sources_by_kind":{"media":1}},"title":"Research proposals diverge on local choice, systemic switching and even systemic omission"}],"medical_affairs_question":"How should Medical Affairs explain cCR and the systemic-versus-local trade-off without implying that surveillance is established care?","sections":{"analysis":[{"id":"section-1","level":2,"title":"High response does not establish safe local-treatment omission"},{"id":"section-2","level":2,"title":"cCR is a composite assessment, not pathological confirmation"},{"id":"section-3","level":2,"title":"ctDNA distinguishes systemic-risk states but can miss local disease"},{"id":"section-4","level":2,"title":"Radiation is neither synonymous with surveillance nor an uncontested substitute"},{"id":"section-5","level":2,"title":"Precursor studies provide motivation, not a single agreed risk conclusion"},{"id":"section-6","level":2,"title":"Feasibility is a clinical and behavioral endpoint"},{"id":"section-7","level":2,"title":"What would a positive or negative NEO-BLAST result mean for patients?"},{"id":"section-8","level":2,"title":"Systemic-first treatment changes sequencing without erasing urgent local needs"},{"id":"section-9","level":2,"title":"Regimen enthusiasm remains conditional on access and the evidence available at the time"},{"id":"section-10","level":2,"title":"Duration, adjuvant value and toxicity complicate de-escalation"},{"id":"section-11","level":2,"title":"Future research is not one uniform bladder-preservation strategy"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F6","shared_claims":6},{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":3}],"id":"T2","label":"Primary endpoint: Metastasis free survival at 2 years (phase 3)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":4}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F3","shared_claims":4},{"id":"F7","shared_claims":2},{"id":"F8","shared_claims":4},{"id":"F9","shared_claims":4}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F4","shared_claims":9},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F7","shared_claims":5},{"id":"F8","shared_claims":1},{"id":"F10","shared_claims":5}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":9}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T12:22:11.869649Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T12:35:30Z","record_hash":"f08f4d4429b8b9e0731d2ef19dc15f6af2780386b3ba8edf9d4fdf51f02d72d1","release_hash":"3345fef4380c4eb0f5061805e90e52cf6ddee0518b3192001abd1b4f4e80e767","report_id":"erudio-nct06537154","run_id":"ae145704-347a-4e31-976b-15e7b8918fcf","schema_version":"5.0","slug":"neo-blast-06537154","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"NEO-BLAST asks whether localized bladder cancer invading muscle can be managed with surveillance rather than cystectomy or chemoradiation after an apparent complete response to neoadjuvant therapy. Commentary comes from X threads, podcasts and YouTube discussions, including physicians with confirmed oncology roles. The discussion turns on how to assess complete response, whether randomization to surveillance is feasible, and which trade-offs patients might accept if surveillance proves non-inferior.","meta_description":"31 sources screened · 211 verified statements (63 from clinicians verified by NPI or staff page) from 23 sources · 11 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-6c8b632279c81ce03fa5"],"id":"F2","paraphrase":"On YouTube, a speaker described in the source as involved in NEO-BLAST asks how complete response can be identified reliably and whether bladder treatment remains necessary for those patients.","publication_caveats":{"reason":"Publication caveats are not stated for this source in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2025-02-17","title":"The proposed cCR assessment is composite; no single negative test establishes eligibility"},{"cited_claim_ids":["claim-945e362a18f124ebc806","claim-26b8fc9cf0c301a837a9","claim-bdf9506e27c937292b54"],"id":"F6","paraphrase":"On YouTube, a speaker described in the source as involved in NEO-BLAST asks whether patients would accept random assignment to surveillance or definitive bladder treatment and continue their allocated care. The interview also asks whether physicians would refer patients and continue treating them within the study.","publication_caveats":{"reason":"Publication caveats are not stated for this source in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-10-08","title":"Randomization feasibility, comparator flexibility and physician participation are substantive concerns"}]},"publication":{"approved_at":"2026-10-31T12:35:30Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":31},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on cystectomy standards and neoadjuvant systemic therapy informing bladder-preservation decisions in muscle-invasive bladder cancer.","Not yet captured in this edition: a view on rigorous complete-response assessment, consistent definitions, and further evidence needed for response-guided bladder preservation.","Not yet captured in this edition: a view on neoadjuvant treatment amendments and adjuvant treatment switching in muscle-invasive bladder cancer.","Not yet captured in this edition: a question about early stopping and interpretation of the available neoadjuvant evidence.","Not yet captured in this edition: a view on pragmatic adaptation of neoadjuvant treatment studies and trade-offs between timely access and treatment heterogeneity.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","73 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources describe planned NEO-BLAST methods and conditional future implications, not comparative evidence establishing surveillance as non-inferior.","Some portions of reviewed recordings and threads were not fully assessed for relevant views. The report therefore cannot claim exhaustive coverage despite including substantial connected discussion.","Missing connected material includes contrasting disappointment about an unpresented pembrolizumab arm, reasoning about limited expected incremental neoadjuvant benefit from single-agent checkpoint treatment, experience with Ambassador and speculation about immature data. These absences limit interpretation of the available systemic-treatment evidence.","Other missing discussion concerns uncertainty about whether another arm had reported, a question about early stopping, and praise for adapting an existing study to include EV–pembrolizumab with faster access, time saved and acknowledged heterogeneity. Another relevant missing view lacks enough detail to characterize.","The separate discussion of whether treatment was standard throughout the perioperative study, including at its start, and the objection to changing a comparator mid-study is not represented. The account of contemporary surgery-control patients must not be read as a complete assessment of comparator selection.","Coverage is also incomplete for a speaker's connected discussion of MODERN amendments and adjuvant treatment changes, including LAG-3 treatment with relatlimab and its melanoma-approval context. Some linked discussion of systemic-treatment efficacy, cystectomy's standard role, rigorous and uniform cCR assessment, consistent definitions and the need for further study is absent. These gaps limit the completeness of the treatment-switch and response-selection themes.","Some speech cannot be assigned to a named participant. It is attributed only to the recording and must not be counted as an additional independent clinician or assumed to contradict a named participant in that recording.","Relayed presentation or podcast views remain the original party's reported views, not the relayer's endorsement. Reposts and parallel-language summaries do not establish independent agreement.","Several clinical roles are not independently established in the sources reviewed. Source-described roles or trial involvement are identified as such; identity information does not establish who spoke otherwise unattributed words.","Precursor-study figures are speakers' reports or interpretations, sometimes approximate or uncertain. They are not NEO-BLAST outcomes and do not establish causation, cross-study equivalence or validated selection rules.","Descriptions of the pilot's 25% threshold differ in their denominator wording. A speaker and the registry describe the joint cCR-and-randomization proportion among enrolled patients; the protocol abstract phrases acceptance among patients with cCR.","The precise Health Canada approval timing for EV–pembrolizumab remains unclear, and easier attainment of the feasibility target is a speaker's expectation rather than a reported feasibility result. The passage describing the 10% non-inferiority margin does not specify its endpoint or timepoint.","No separate protocol file was available from the registry. The registry methods and protocol publication provide context, not a complete assessment of every operational or safety question.","Source dates are publication or post dates unless an event is explicitly named. They cannot establish a readout date, a session date or a change in a person's position.","The report describes this edition's reviewed discussion, not the prevalence of views among HCPs or all public commentary."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":1,"registry":1,"regulatory":0,"x_thread":13,"x_video":1,"youtube":4},"by_evidence_role":{"commentary":21,"context":1,"methods":1},"count":23,"evidence_window":{"end":"2026-10-31","start":"2025-02-17"},"retrieval_snapshot":"2026-10-31T11:21:51.337934Z","timeline":[{"count":1,"week":"2025-W08"},{"count":2,"week":"2025-W20"},{"count":1,"week":"2025-W21"},{"count":2,"week":"2025-W26"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2026-W09"},{"count":2,"week":"2026-W11"},{"count":2,"week":"2026-W15"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W29"},{"count":3,"week":"2026-W31"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W41"},{"count":2,"week":"2026-W44"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT06537154:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06537154:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42567733","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:46c54d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:66efae","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7fc1fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1913306664125575438:9283e7be-b3de-4c43-a0e8-68af6a2f0d3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916911296244813994:d25fa1c8-4394-4904-befb-f25ae47bbf51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1917281535100604516:206fbe5f-7733-4c7f-94f9-15600feb0442","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1923740400616911025:da209df7-5e37-41be-82bc-0323a228efaf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1931395803425255439:ad5765b2-2e8b-4a40-a8f5-07d1f210eca7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938584717164498967:19e12243-fd77-4fe1-8c53-e9c92a78cdc4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938585232371765322:96ecc998-89ba-4bfa-a714-53ed6ff101ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1943641545074266194:08ce8424-9af2-4ab3-a134-96b156fb024a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1953863895732441595:d905e084-e763-4b37-95ac-8bec465cbd08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027526081805488284:a686b787-d422-49cd-9c48-ee770c4e519f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032756983955071074:2d5dbeb3-a5d0-404f-be31-6891eac02d11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033213594402160737:967a3fd2-b78b-4cb4-b04c-599ce215720d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2042101235109556400:5afc67c1-ceee-467e-a33c-dfecc8df2f7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051563805709144552:157ce7e4-f527-4083-b5e0-ffbd7cafde64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051571738467602492:837e4741-67e5-4ad1-88c7-1216276b95d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2077660280230723645:cbc75947-62f6-4567-bedc-44435d50f056","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081717673587564890:3aaefefd-e6de-4f7d-85ed-bcefdd33554a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082162359502594379:642c9224-f1f1-499b-97ae-460fe64839c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2083577159545966699:cdfd3340-8061-4427-9bcc-2cb5cb4d7a79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086784632767566320:2adee53f-6a63-4765-89d6-0c915a8dec63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095876668518785531:d0e065ea-e87c-4e76-a67d-2e96c718da94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109712782719676784:dc1b8cba-32e0-4d07-b66b-5bef14fc7450","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115388635365228679:e729d017-dfe6-4a54-9817-413843501d7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1923740400616911025","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Ahh-f1eU4LQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:JVAOGb0K_4g","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:aisyUXOLbyc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:sqwJ25X2aY8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":23,"x_video":1,"youtube":4},"by_evidence_role":{"commentary":31},"count":31,"evidence_window":{"end":"2026-10-31","start":"2025-02-17"},"retrieval_snapshot":"2026-10-31T11:21:51.337934Z","timeline":[{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W16"},{"count":2,"week":"2025-W18"},{"count":2,"week":"2025-W20"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W23"},{"count":2,"week":"2025-W26"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W32"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2026-W09"},{"count":2,"week":"2026-W11"},{"count":2,"week":"2026-W15"},{"count":2,"week":"2026-W19"},{"count":1,"week":"2026-W29"},{"count":3,"week":"2026-W31"},{"count":1,"week":"2026-W33"},{"count":2,"week":"2026-W36"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":2,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"reason":"Unmapped registry condition: Muscle-Invasive Bladder Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"NEO-BLAST","aliases":["NEO-BLAST","NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment","Active Surveillance Versus Definitive Local Therapy for Patients Showing Clinical Complete Response Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer"],"brief_title":"NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment","collaborators":["University of British Columbia","Canadian Institutes of Health Research (CIHR)"],"conditions":["Muscle-Invasive Bladder Carcinoma"],"display_condition":"muscle-invasive bladder cancer with clinical complete response","display_interventions":[],"enrollment":{"count":688,"type":"ESTIMATED"},"interventions":[{"name":"Active Surveillance","synonyms":["Clinical restaging (utDNA, ctDNA, MRI and TURBT)"],"type":"PROCEDURE"},{"name":"Control arm - Definitive bladder treatment","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"}],"nct_id":"NCT06537154","official_title":"Active Surveillance Versus Definitive Local Therapy for Patients Showing Clinical Complete Response Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"Feasibility to randomized patients with cCR to either active surveillance or definitive bladder treatment.","measure":"Proportion of patients found to have a cCR and randomized on the number of patients enrolled (pilot-RCT ; phase 2)","timeFrame":"24 months"},{"description":"Time to metastasis, defined as \\>cN1 (more than 1 clinically suspicious lymph nodes), cT4a (unresectable disease), or M1 disease or death.","measure":"Metastasis free survival at 2 years (phase 3)","timeFrame":"24 months"}],"registered_date":{"date":"2024-08-05","type":"ACTUAL"},"registry_last_updated":"2025-07-30","registry_url":"https://clinicaltrials.gov/study/NCT06537154","short_name":"NEO-BLAST","short_name_basis":"registry_acronym","sponsor":"Peter Black","start_date":{"date":"2025-07-28","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"H23-02447","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}